(July 2, 2013) -- When the Supreme Court recently ruled that pay-for-delay agreements between brand and generic drug companies are subject to antitrust scrutiny, officials at the Federal Trade Commission had every right to feel vindicated. The agency has waged a protracted fight to challenge these deals and had lost more than it had won in federal appellate courts....